Oxygenta Pharmaceutical Limited (BOM:524636)
India · Delayed Price · Currency is INR 52.11
+1.20 (2.36%)
At close: Jul 27, 2026
Oxygenta Pharmaceutical Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 1,348 | 1,130 | 1,093 | 396.42 | 309.88 | 605.25 |
Other Revenue | -1.46 | - | - | - | -0 | 0 |
| 1,347 | 1,130 | 1,093 | 396.42 | 309.87 | 605.25 | |
Revenue Growth | 20.47% | 3.37% | 175.71% | 27.93% | -48.80% | 16.33% |
Cost of Revenue | 1,174 | 1,021 | 1,071 | 405.89 | 300.79 | 564.29 |
Gross Profit | 172.73 | 108.46 | 21.86 | -9.47 | 9.08 | 40.96 |
Selling, General & Admin | 75.96 | 76.45 | 70.52 | 61.74 | 60.42 | 7.87 |
Other Operating Expenses | 178.12 | 185.68 | 46.67 | 25.65 | 19.83 | 18.33 |
Operating Expenses | 275.02 | 285.36 | 125.35 | 113.99 | 100.77 | 42.12 |
Operating Income | -102.3 | -176.89 | -103.5 | -123.46 | -91.69 | -1.15 |
Interest Expense | -66.08 | -47.77 | -20.17 | -15.81 | -14.75 | -9.15 |
Interest & Investment Income | - | - | 0.23 | 0.18 | 0.05 | 0.04 |
Currency Exchange Gain (Loss) | - | - | -1.59 | 0.14 | 0.13 | - |
Other Non Operating Income (Expenses) | 2.86 | 2.86 | 12.21 | -0.13 | -0.13 | -0.1 |
EBT Excluding Unusual Items | -165.51 | -221.8 | -112.82 | -139.09 | -106.38 | -10.36 |
Gain (Loss) on Sale of Assets | - | - | 0.49 | - | - | - |
Other Unusual Items | 0.12 | - | -3.2 | 0.37 | -7.34 | 5.46 |
Pretax Income | -165.4 | -221.8 | -115.53 | -138.72 | -113.73 | -4.89 |
Income Tax Expense | -29.7 | -46.09 | -18.7 | -103.92 | 1.98 | 1.21 |
Net Income | -135.69 | -175.72 | -96.83 | -34.79 | -115.71 | -6.1 |
Net Income to Common | -135.69 | -175.72 | -96.83 | -34.79 | -115.71 | -6.1 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 37 | 37 | 36 | 32 | 14 | 13 |
Shares Outstanding (Diluted) | 37 | 37 | 36 | 32 | 14 | 13 |
Shares Change | 1.23% | 2.91% | 12.20% | 125.61% | 11.43% | - |
EPS (Basic) | -3.67 | -4.75 | -2.69 | -1.09 | -8.15 | -0.48 |
EPS (Diluted) | -3.67 | -4.75 | -2.69 | -1.09 | -8.15 | -0.48 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -406.1 | -87.89 | -171.55 | -112.79 | -66.26 |
Free Cash Flow Per Share | - | -10.98 | -2.44 | -5.35 | -7.94 | -5.20 |
Gross Margin | 12.82% | 9.60% | 2.00% | -2.39% | 2.93% | 6.77% |
Operating Margin | -7.59% | -15.66% | -9.47% | -31.14% | -29.59% | -0.19% |
Profit Margin | -10.07% | -15.55% | -8.86% | -8.78% | -37.34% | -1.01% |
Free Cash Flow Margin | - | -35.94% | -8.04% | -43.28% | -36.40% | -10.95% |
EBITDA | -75.3 | -153.67 | -95.34 | -96.85 | -71.17 | 14.76 |
EBITDA Margin | -5.59% | -13.60% | -8.72% | -24.43% | -22.97% | 2.44% |
D&A For EBITDA | 26.99 | 23.23 | 8.16 | 26.61 | 20.52 | 15.91 |
EBIT | -102.3 | -176.89 | -103.5 | -123.46 | -91.69 | -1.15 |
EBIT Margin | -7.59% | -15.66% | -9.47% | -31.14% | -29.59% | -0.19% |
Revenue as Reported | 1,350 | 1,133 | 1,106 | 396.85 | 310.05 | 605.29 |